Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says

11:28 AM EST, 11/03/2026 (MT Newswires) -- Axsome Therapeutics (AXSM) could achieve earnings in 2027, backed by its recent financials and growing revenue from Auvelity, RBC Capital Markets said in a note Monday. The company reported a Q3 net loss Monday of $0.25 per diluted share, narrowing from a loss of $0.94 a year earlier, as revenue rose to $259.7 million from $171.0 million. Net product sales from Auvelity were $207.6 million, in line with Street expectations, the investment firm said. RBC said Auvelity's revenue trajectory from its additional indication of Alzheimer's disease agitation, or ADA, is still developing and launch should ramp although potentially slower than the earlier indication of major depressive disorder, or MDD. Auvelity gives the company a $1.7 billion revenue opportunity in ADD by 2035, and $2.2 billion from MDD, the investment firm said. RBC Capital Markets has an outperform rating on Axsome Therapeutics, with a lower price target of $273 from $295. Shares of Axsome Therapeutics were up more than 5% in Tuesday trading. Price: 143.03, Change: +7.02, Percent Change: +5.16